The US Food and Drug Administration says 48 decisions on human drug applications remain delayed by the difficulty of inspecting or assessing manufacturing facilities during the pandemic, including six considered to be mission-critical cases.
The agency has scheduled those mission-critical inspections for later this fiscal year, which ends 30 September.